Blocking tumour protein FAK releases checkpoint brake making ovarian cancer susceptible to immunotherapy
Whether it’s a caterpillar constructing a cocoon or kids building a den, forming a protective environment around yourself is a good strategy. Unfortunately, cancer cells appear to know this trick too, and ovarian tumours protect themselves from many chemotherapy and immunotherapy treatments. A new study has examined this defensive strategy, searching for potential weaknesses. Many immunotherapies aim to unleash the immune system by releasing natural molecular brakes called checkpoint receptors. The researchers discovered that in ovarian cancer tissue (pictured), a protein called focal-adhesion kinase (FAK, highlighted in green) regulates CD155 (red), a protein that binds to these receptors. Maintaining high levels of CD155 keeps immune cells (pink) at bay. Experiments that both subdued FAK and blocked the receptors increased the immune response to the cancer, resulting in smaller tumours and increasing survival, raising hopes that a similar strategy could help patients, who currently have very limited treatment options.
BPoD stands for Biomedical Picture of the Day. Managed by the MRC London Institute of Medical Sciences the website aims to engage everyone, young and old, in the wonders of biomedicine. Images are kindly provided for inclusion on this website through the generosity of scientists across the globe.
BPoD is also available in Catalan at www.bpod.cat with translations by the University of Valencia.